Omeros' knee surgery drug fails in late-stage study
(Reuters) - Omeros Corp (OMER.O) said a late-stage trial of its experimental drug for patients undergoing knee surgery did not meet its main goal, sending the company's shares down as much as 10 percent in extended trade.
The company said the drug -- codenamed OMS103HP -- did not meet a patient-reported measure that comprised questions about knee swelling and stiffness.
A second late-stage trial on the drug remains on track and will begin in the first half of 2013, said the company that focuses on treating inflammation and disorders of the central nervous system.
Omeros's shares were down 6 percent at $5.50 after the bell on Thursday. (Reporting by Prateek Kumar; Editing by Sreejiraj Eluvangal)
- Special Report: Thailand secretly supplies Myanmar refugees to trafficking rings |
- UPDATE 2-China bars banks from bitcoin transactions
- The 10 Most Corrupt and Least Corrupt Countries in the World
- Obama says he's not allowed iPhone for 'security reasons'
- JPMorgan warns 465,000 card users on data loss after cyber attack